Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Recalcitrant Plaque-type Psoriasis
NCT00521339Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2007
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apremilast in plaque psoriasis, sponsored by Amgen. Primary endpoint: Treatment Emergent Adverse Events. Started Aug 2007; status: completed.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00521339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00521339.